title: Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome.
abstract: BACKGROUND
  Adults with polycystic ovary syndrome (PCOS) may be at increased risk for metabolic syndrome (MBS) and related cardiovascular disease. It is not clear whether PCOS diagnosed in adolescence increases the risk of MBS in this age group.
  
  
  OBJECTIVE
  The aim was to compare the prevalence and related characteristics of MBS in obese adolescents with and without PCOS.
  
  
  METHODS
  We conducted a cross-sectional study of overweight and obese PCOS adolescents and BMI matched controls.
  
  
  METHODS
  A total of 74 subjects, 43 with PCOS and 31 controls, participated in the study.
  
  
  METHODS
  Each subject underwent a physical examination and laboratory evaluation for a diagnosis of MBS. Regional fat distribution was determined by computerized tomography scan in the PCOS adolescents.
  
  
  METHODS
  We measured the prevalence of MBS and its components in adolescent subjects and controls.
  
  
  RESULTS
  The PCOS group had larger ovarian volume and higher measures of total testosterone and free androgen index than controls, but there were no differences in waist circumference, fasting glucose, blood pressure, or lipids. PCOS adolescents demonstrated more glucose abnormalities and higher plasminogen activator inhibitor-1. By pediatric criteria, 53% of the PCOS and 55% of the control adolescents had MBS. By adult criteria, 26% of PCOS and 29% of controls met diagnostic criteria for MBS.
  
  
  CONCLUSIONS
  Obese adolescent women have a high prevalence of MBS, and PCOS does not add additional risk for MBS. There appears to be an association between MBS and visceral adiposity. PCOS is associated with increased incidence of glucose intolerance and increased plasminogen activator inhibitor-1. Our results reinforce the importance of obesity counseling in adolescents to recognize the possible risk of future cardiovascular disease in these young women.
authors.affiliation: Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
authors.forename: Brooke
authors.initials: B
authors.lastname: Rossi
authors.forename: Sara
authors.initials: S
authors.lastname: Sukalich
authors.forename: Jennifer
authors.initials: J
authors.lastname: Droz
authors.forename: Adam
authors.initials: A
authors.lastname: Griffin
authors.forename: Stephen
authors.initials: S
authors.lastname: Cook
authors.forename: Aaron
authors.initials: A
authors.lastname: Blumkin
authors.forename: David S
authors.initials: DS
authors.lastname: Guzick
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: Hoeger
mesh_terms: D000273:Adipose Tissue / Q000473:pathology; D050154:Adiposity / Q000502:physiology; D000293:Adolescent; D000886:Anthropometry; D015415:Biomarkers; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000502:physiology; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000150:complications / Q000453:epidemiology; D002648:Child; D008076:Cholesterol, HDL / Q000097:blood; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D024821:Metabolic Syndrome / Q000150:complications / Q000453:epidemiology*; D009765:Obesity / Q000150:complications / Q000453:epidemiology*; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000453:epidemiology*; D012307:Risk Factors; D014057:Tomography, X-Ray Computed; D014280:Triglycerides / Q000097:blood; D055105:Waist Circumference
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D008076:Cholesterol, HDL; D017395:Plasminogen Activator Inhibitor 1; D014280:Triglycerides